nsclc - Robuta Search

https://pubmed.ncbi.nlm.nih.gov/32722386/ Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment Locally advanced non-small cell lung cancer accounts for one third of non-small cell lung cancer (NSCLC) at the time of initial diagnosis and presents with a... small cell lung cancer https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1275957/full Frontiers | Histological transformation into SCLC: An important resistance mechanism of NSCLC upon... The phenomenon of histological transformation has been widely reported in advanced non-small cell lung cancer (NSCLC) with EGFR mutations following the failu... https://pubmed.ncbi.nlm.nih.gov/27843640/ Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence Epidermal growth factor receptor (EGFR) plays a key role in tumour evolution, proliferation and immune evasion, and is one of the most important targets for... https://pubmed.ncbi.nlm.nih.gov/36979929/ Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion... The FDA approval of amivantamab-vmjw, the first bispecific antibody to target the exon20ins mutation, represents an important advancement in the treatment of... https://pubmed.ncbi.nlm.nih.gov/36008805/?dopt=Abstract METTL3 promotes non-small cell lung cancer (NSCLC) cell proliferation and colony formation in a... Our study reveals that METTL3-FRAS1 plays a crucial role in NSCLC cell proliferation, colony formation, and tumor growth through the regulation of CDON by... small cell lung cancer https://www.lumakras.com/ NSCLC and mCRC Treatment | LUMAKRAS® (sotorasib) nsclc mcrc treatment sotorasib https://pubmed.ncbi.nlm.nih.gov/27928026/ AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases Non-small-cell lung cancer patients with activating mutations in epidermal growth factor receptor (EGFR) respond to EGFR tyrosine kinase inhibitor (TKI)... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1382197/full Frontiers | Three-year follow-up study reveals improved survival rate in NSCLC patients underwent... Background: No studies in China have assessed the guideline-concordance level of the first-course of non-small cell lung cancer (NSCLC) diagnosis and treatme... https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1521828/full Frontiers | SMARCA4-deficient NSCLC treated with first-line tislelizumab and fruquintinib achieved... SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) typically lacks target-driven gene alterations and are primarily resistant to cytotoxic drugs. ... https://oru.diva-portal.org/smash/record.jsf?pid=diva2:529647 Oestrogen receptor ss in NSCLC : prevalence, proliferative influence, prognostic impact and smoking https://www.findkrasg12c.com/ Prevalence & Testing for KRAS G12C Mutation in NSCLC Learn about how ~13 percent of non-small cell lung cancer patients go undetected if not tested for the KRAS G12C mutation. prevalence testing kras mutation nsclc https://portal.fis.tum.de/en/publications/stereotactic-body-radiotherapy-for-centrally-located-stagei-nsclc/ Stereotactic body radiotherapy for centrally located stage I NSCLC: A multicenter analysis -... centrally located https://pure.psu.edu/en/publications/prediction-of-distant-metastases-after-stereotactic-body-radiatio/ Prediction of Distant Metastases After Stereotactic Body Radiation Therapy for Early Stage NSCLC:... https://pure.psu.edu/en/publications/characterization-of-met-exon-14-skipping-alterations-in-nsclc-and/ Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential... https://adjuvantgx.com/ Improving NSCLC Treatment Outcomes | Adjuvant Genomics Adjuvant Genomics provides cutting-edge genomic insights for NSCLC patients, empowering oncologists with a risk and treatment response score. treatment outcomes improving nsclc adjuvant genomics https://publikationen.uni-tuebingen.de/xmlui/handle/10900/165627 Feasibility of Non-Invasive Sentinel Lymph Node Identification in Early-Stage NSCLC Through... sentinel lymph node https://ub01.uni-tuebingen.de/xmlui/handle/10900/165627 Feasibility of Non-Invasive Sentinel Lymph Node Identification in Early-Stage NSCLC Through... sentinel lymph node https://pmc.ncbi.nlm.nih.gov/articles/PMC10308181/ Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early... Continuous revision of the histologic and stage-wise classification of lung cancer by the World Health Organization (WHO) provides the foundation for... https://pubmed.ncbi.nlm.nih.gov/27388325/ Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in... Results observed in this case encourage further research on the activity of sorafenib in both HCC and NSCLC, based on the presence of BRAF mutation. This could... https://www.researchandmarkets.com/reports/5947900/non-small-cell-lung-cancer-nsclc-epidemiology Non-Small Cell Lung Cancer (Nsclc): Epidemiology Forecast to 2032 Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases (National Cancer... small cell lung cancer non nsclc epidemiology forecast https://anesthesiology.weill.cornell.edu/publications/identification-of-reprogrammed-myeloid-cell-transcriptomes-in-nsclc Identification of Reprogrammed Myeloid Cell Transcriptomes in NSCLC. | Department of Anesthesiology identification reprogrammed myeloid cell transcriptomes https://scholarworks.indianapolis.iu.edu/items/febf9285-e7f1-4837-8e4b-1a7da7ae93cf Mutations associated with high-grade irAEs in NSCLC patients receiving immunotherapies Objectives: Compared to low-grade irAEs, high-grade irAEs are more often dose-limiting and can alter the long-term treatment options for a patient. Predicting... associated with high grade mutations https://pubmed.ncbi.nlm.nih.gov/41137928/ NHOC/NHOP as novel biomarkers for predicting lymph node metastasis in NSCLC using PET/CT radiomics... This study established an accurate, interpretable machine learning model for preoperative prediction of LNM and ONM in NSCLC. NHOC emerged as a novel... https://www.researchandmarkets.com/reports/6219866/braf-mutated-non-small-cell-lung-cancer BRAF Mutated Non-small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology, and Market Forecast... BRAF Mutated Non-small Cell Lung Cancer (NSCLC) - Market Insight, Epidemiology, and Market Forecast - 2036 small cell lung cancer https://pubmed.ncbi.nlm.nih.gov/35724798/ Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had... Befotertinib of 75 to 100 mg has satisfying efficacy and manageable toxicity in patients with locally advanced or metastatic NSCLC harboring T790M mutation... https://research.rug.nl/nl/publications/regional-differences-in-predictive-biomarker-testing-rates-for-pa/ Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in... regional differences biomarker testing https://pubmed.ncbi.nlm.nih.gov/33114576/ The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved... Treatment with inhibition of programmed cell death 1 (PD-1) or its ligand (PD-L1) improves survival in advanced non-small-cell lung cancer (NSCLC).... https://pmc.ncbi.nlm.nih.gov/articles/PMC9168140/ Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of... NSCLC is a solid tumor with a growing number of actionable biomarkers that may inform treatment. Current guidelines recommend a broad, panel-based approach be... in the united states https://pubmed.ncbi.nlm.nih.gov/39089004/ Befotertinib for patients with pretreated EGFR T790M mutated locally advanced or metastatic NSCLC:... Befotertinib demonstrated a more profound OS benefit compared to other 3rd-generation EGFR TKI, despite that cross trial data comparison should be interpreted... https://pubmed.ncbi.nlm.nih.gov/33282740/ High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With... Bone metastatic NSCLC patients with EGFR mutated disease, treated with EGFR TKIs, have a relatively long survival expectancy and are at high risk to develop... https://pubmed.ncbi.nlm.nih.gov/31860648/ Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients This study indicates the feasibility of circulating tumor nucleic acids (ctNA) analysis as a tumor biopsy surrogate in clinical practice for NSCLC personalized... liquid biopsy clinical feasibility ngs analysis https://pubmed.ncbi.nlm.nih.gov/32486453/ Association of a CT-Based Clinical and Radiomics Score of Non-Small Cell Lung Cancer (NSCLC) with... a combined clinical-radiomics model was not superior to a single clinical or single radiomics model to predict positive LNs. A radiomics model was able to... https://www.news-medical.net/news/20151211/Alecensa-(alectinib)-approved-for-treatment-of-people-with-advanced-ALK-positive-NSCLC.aspx Alecensa (alectinib) approved for treatment of people with advanced ALK-positive NSCLC Jun 19, 2019 - The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer... https://scholars.duke.edu/publication/1054215 Scholars@Duke publication: Afatinib induces apoptosis in NSCLC without EGFR mutation through... https://pure.psu.edu/en/publications/first-line-chemotherapy-for-nsclc-an-overview-of-relevant-trials/ First-line chemotherapy for NSCLC: An overview of relevant trials - Penn State first line an overview https://ods.od.nih.gov/Funding/abstract.aspx?g=5R01CA095568-03 Grant Abstract: Biomarkers to Assess Selenium Chemoprevention for NSCLC grant abstract biomarkers assess selenium https://scholarshare.temple.edu/entities/publication/fe0e16c8-c1a7-4ff9-bdc8-eeba603fd72c Tumor-targeted SN38 inhibits growth of early stage non-small cell lung cancer (NSCLC) in a KRas/p53... Non-small cell lung cancer (NSCLC) is the leading cause of cancer death worldwide, with a 5-year survival of only ~16%. Potential strategies to address NSCLC... https://pubmed.ncbi.nlm.nih.gov/39544299/ Editorial: Advances in the use of EGFR TKIs in the treatment of NSCLC Editorial: Advances in the use of EGFR TKIs in the treatment of NSCLC in the editorial advances use egfr https://researchprofiles.ku.dk/en/publications/durable-response-to-sequential-ros1-tkis-in-metastatic-squamous-n/ Durable Response to Sequential ROS1-TKIs in Metastatic Squamous NSCLC With EZR-ROS1 Fusion: A... https://en.wikibooks.org/wiki/Radiation_Oncology/Lung/NSCLC/NSCLC_PCI Radiation Oncology/NSCLC/PCI - Wikibooks, open books for an open world radiation oncology open books nsclc pci wikibooks https://pubmed.ncbi.nlm.nih.gov/38012986/ Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC Our real-world multicenter analysis revealed that amivantamab is a potentially effective treatment option for patients with EGFR mutations outside of exon 20... efficacy and safety real world https://cme.bu.edu/NSCLC Improving Biomarker Driven Precision Therapy in NSCLC: Less Common, More Complex: Multidisciplinary... https://boris-portal.unibe.ch/entities/publication/9070dab1-f30b-4032-89c5-22b9b37866d8 Outcomes in Patients With Resectable Stage III NSCLC Who Did Not Have Definitive Surgery After... Introduction Neoadjuvant or perioperative treatment, including an immune checkpoint inhibitor (ICI), has emerged as a new standard for patients with resectable... https://www.mdpi.com/1422-0067/24/3/2648 Discovery of Small Molecule COX-1 and Akt Inhibitors as Anti-NSCLC Agents Endowed with... Targeted therapies have come into prominence in the ongoing battle against non-small cell lung cancer (NSCLC) because of the shortcomings of traditional... https://scholars.lib.ntu.edu.tw/entities/publication/bff708a6-fe59-4bb6-93c6-9f8636bf7097 Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy... Result from BR. 21 study demonstrated that in unselected patients with advanced non-small cell lung cancer (NSCLC) pretreated with standard first-line or... https://pubmed.ncbi.nlm.nih.gov/34556984/?dopt=Abstract Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in... Collectively, these findings indicated that anlotinib-resistant NSCLC cell-derived exosomal miR-136-5p confers anlotinib resistance in NSCLC cells by targeting... https://www.businesswire.com/news/home/20220910005015/en/Spectrum-Pharmaceuticals-Announces-Data-from-Poster-Presentation-for-Poziotinib-in-NSCLC-Patients-with-G778_P780dup-HER2-Exon-20-Mutations-at-ESMO-Congress-2022 Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients... Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced data from a po... poster presentation https://pubmed.ncbi.nlm.nih.gov/28074905/?dopt=Abstract MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC)... Our previous studied indicated that eukaryotic translation initiation factor 3a (eIF3a) increases the sensitive of platinum-based chemotherapy in lung cancer.... small cell lung cancer https://ce.massmed.nejm.org/nejm-weekly-cme/content/amivantamab-plus-chemotherapy-nsclc-egfr-exon-20-insertions Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions | MMS/NEJM Continuing Education... https://pubmed.ncbi.nlm.nih.gov/38149055/ Case report: SAF-189s is a potent inhibitor in a lorlatinib-resistant NSCLC patient with acquired... Acquired anaplastic lymphoma kinase (ALK) mutation is the major resistant mechanism to ALK tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer... https://bibliographie.uni-tuebingen.de/xmlui/handle/10900/118317 Metastasis directed stereotactic radiotherapy in NSCLC patients progressing under targeted- or... stereotactic radiotherapy metastasis directed https://www.mdpi.com/2072-6694/16/10/1825 Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1... The efficacy of immune checkpoint inhibitor (ICI) therapy concerning programmed death ligand 1 (PD-L1) status is well established in patients diagnosed with... https://pubmed.ncbi.nlm.nih.gov/37907052/ Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib... This study affirms the efficacy of lorlatinib in patients with ALK-positive SCLC transformation harboring the V1180L mutation. Furthermore, it underscores the... https://www.research.va.gov/about/funded_research/proj-details-FY2019.cfm?pid=642345 I01CX002007-01 - Induction of Senescence using Dexamethasone to re-sensitize NSCLC to anti-PD1... https://pubmed.ncbi.nlm.nih.gov/34208765/ Dynamic Evaluation of Circulating miRNA Profile in EGFR-Mutated NSCLC Patients Treated with... Our study provides interesting insights on the role of circulating miRNAs, in particular miR-21, and their dynamic change over time in predicting EGFR-TKI... https://edrn.cancer.gov/data-and-resources/publications/32138766-3086-ultrasensitive-dna-hypermethylation-detection-using-plasma-for-early-detection-of-nsclc-a-study-in-chinese-patients-with-very-small-nodules/ Ultrasensitive DNA hypermethylation detection using plasma for early detection of NSCLC: a study in... This is a publication by a member of the Early Detection Research Network. https://pubmed.ncbi.nlm.nih.gov/38347643/ Oncogenic alterations in advanced NSCLC: a molecular super-highway Lung cancer ranks among the most common cancers world-wide and is the first cancer-related cause of death. The classification of lung cancer has evolved... advanced nsclc alterations molecular super highway https://jcopodcast.libsyn.com/webpage/jco-article-insights-tropion-lung01-dato-dxd-in-nsclc Journal of Clinical Oncology (JCO) Podcast: JCO Article Insights: TROPION-Lung01 Dato-DXd in NSCLC In this JCO Article Insights episode, Ece Cali summarizes findings from the JCO article, "" TRANSCRIPT Ece Cali: Hello and welcome to the . I'm your host Ece... journal of clinical oncology https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.1095947/full Frontiers | Editorial: Immunotherapy for NSCLC with oncogenic driver variants targeted therapy resistance4, immune checkpoint inhibitors5.Immune checkpoint inhibitor (ICI) has been recognized as a gold standard treatment for advanced 2... frontiers editorial immunotherapy nsclc driver https://www.news-medical.net/news/20230519/Study-finds-socio-economic-inequalities-in-access-to-novel-therapies-for-many-NSCLC-patients.aspx Study finds socio-economic inequalities in access to novel therapies for many NSCLC patients May 19, 2023 - Novel anti-cancer therapies were not accessible to more than half of the patients in England who were diagnosed with non-small cell lung cancer, according to a... https://www.cruk.cam.ac.uk/publications/osimertinib-benefit-in-egfrmutant-nsclc-patients-with-t790mmutation-detected-by-circulating-tumour-dna/ Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating... Authors: J Remon, C Caramella, C Jovelet, L Lacroix, A Lawson, S Smalley, K Howarth, D Gale, E Green, V Plagnol, N Rosenfeld, D Planchard, MV Bluthgen, A... https://pmc.ncbi.nlm.nih.gov/articles/PMC9039869/ Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected NSCLC in a High... Complete and accurate pathology reports are vital to postoperative prognostication and management. We evaluated the impact of three interventions across a... https://www.mdpi.com/2072-6643/16/10/1458 Anthocyanins in Non-Small Cell Lung Cancer (NSCLC) Treatment and Prevention An ever-growing volume of data supports the important role of dietary interventions in cancer prevention and the beneficial effects of plant secondary... small cell lung cancer anthocyanins non https://adisinsight.springer.com/trials/700246912?error=cookies_not_supported&code=ea2aa400-993d-46bb-b38d-bf23866bb302 First Line Treatment of Elderly Patients With Advanced or Metastatic NSCLC With Docetaxel and... The investigators propose to study the efficacy and safety of the combination of Docetaxel plus Bevacizumab in a Phase II trial of elderly subjects with https://boris-portal.unibe.ch/entities/publication/c5ec99f3-96e2-4e2a-9d23-cac580a420b8 Is Hypofractionation a Good Idea in Radiotherapy for Locally Advanced NSCLC? a good idea https://www.prnewswire.com/news-releases/tepmetko-continues-to-strengthens-its-position-as-a-leading-metex14-skipping-nsclc-therapy--delveinsight-302394095.html TEPMETKO Continues to Strengthens its Position as a Leading METex14 Skipping NSCLC Therapy |... /PRNewswire/ -- DelveInsight's "TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase inhibitor... https://scholarshare.temple.edu/entities/publication/fad3037e-68e3-47ea-8fe8-b6cc834ce4d3 A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and... The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small Cell Lung Cancer (NSCLC) launched the era of personalized medicine in advanced... https://www.news-medical.net/news/20260421/Phase-I-NSCLC-trials-shrink-and-cluster-in-major-US-cities.aspx Phase I NSCLC trials shrink and cluster in major U.S. cities Apr 21, 2026 - Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted... phase i https://pubmed.ncbi.nlm.nih.gov/33172113/ Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and... The treatment of patients affected by non-small cell lung cancer (NSCLC) has been revolutionised by the discovery of druggable mutations. ROS1 (c-ros oncogene)... small cell lung cancer https://pubmed.ncbi.nlm.nih.gov/29864943/ Biochemical and computational evaluation of Triptolide-induced cytotoxicity against NSCLC Triptolide is the major bioactive component isolated from the Chinese Medicinal plant Tripterygium wilfordii. Despite the growing interest and the plethora of... biochemical computational evaluation triptolide induced https://www.news-medical.net/news/20191106/Study-Pleural-effusions-are-linked-with-NSCLC-and-malignant-mesothelioma.aspx Study: Pleural effusions are linked with NSCLC and malignant mesothelioma Nov 6, 2019 - Cryopreserved cell-free PE fluid from 101 NSCLC patients, 8 mesothelioma and 13 with benign PE was assayed for a panel of 40 cytokines/chemokines using the... study pleural linked nsclc malignant https://palliative-references.stanford.edu/publications/chinese-american/variability-survival-outcomes-among-asian-ethnic-groups-stage-iv Variability in Survival Outcomes Among Asian Ethnic Groups with Stage IV NSCLC | Palliative... https://pubmed.ncbi.nlm.nih.gov/35274459/ Structure Modification of FXR Antagonistic Chalcones and Their Inhibitory Effects on NSCLC Cell... Although the farnesoid X receptor (FXR) has been regarded as a promising drug target for metabolic diseases as well as anti-inflammatory, antitumor and... https://pure.psu.edu/en/publications/timp-1-mediated-chemoresistance-via-induction-of-il-6-in-nsclc/ TIMP-1-mediated chemoresistance via induction of IL-6 in NSCLC - Penn State https://www.researchandmarkets.com/reports/5025136/anaplastic-lymphoma-kinase-non-small-cell-lung Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) - Market Insight, Epidemiology... Anaplastic lymphoma kinase Non-Small Cell Lung Cancer (ALK-NSCLC) - Market Insight, Epidemiology and Market Forecast - 2034 small cell lung cancer https://pubmed.ncbi.nlm.nih.gov/33924231/ AQP3 Increases Intercellular Cohesion in NSCLC A549 Cell Spheroids through Exploratory Cell... Tumor cell aggregation is critical for cell survival following the loss of extracellular matrix attachment and dissemination. However, the underlying... increases cohesion https://research-repository.uwa.edu.au/en/publications/sunvozertinib-for-nsclc-patients-with-egfr-exon-20-insertion-muta/ Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: Preliminary analysis of... https://clarivate.com/life-sciences-healthcare/report/unneon0041-2026-biopharma-non-small-cell-lung-cancer-unmet-need-unmet-need-metastatic-nsclc-without-driver-mutations-us/ Non-Small-Cell Lung Cancer - Unmet Need - Unmet Need - Metastatic NSCLC without driver mutations... First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or... small cell lung cancer unmet need https://pmc.ncbi.nlm.nih.gov/articles/PMC8307492/ A Nationwide Study on the Impact of Routine Testing for EGFR Mutations in Advanced NSCLC Reveals... The presence of an EGFR activating mutation in tumors of non-small-cell lung cancer patients enables effective targeted therapy towards EGFR. Studies that... https://pubmed.ncbi.nlm.nih.gov/42000138/ Navigating controversies in stage III NSCLC: a multidisciplinary case discussion on evolving... The case underscores current controversies in the management of stage III NSCLC and the critical role of the MDT. While neoadjuvant and perioperative... stage iii https://thisistheway2023.podbean.com/e/the-pulmonologists-role-in-precision-medicine-for-nsclc/ SAB Webinar: The pulmonologist's role in precision medicine for NSCLC | This is The Way Podcast In this episode of "This is the Way" Podcast, Dr. Jaspal Singh moderates the discussion between Drs. Fox and Silvestri on the pulmonologist's role in precision... https://tobias-lib.ub.uni-tuebingen.de/xmlui/handle/10900/130663 Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC... t cells https://boris-portal.unibe.ch/entities/publication/28895110-2d27-4c4b-98cb-dfb78bcd72b2 Does omitting the clinical target volume in stereotactic radiotherapy for NSCLC affect oncologic... Aims The use of CTV margins in lung SBRT is not a standard practice due to historically high local control (LC) rates and concerns about toxicity. However,... https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-10275&loc=0&rl=2&tid=PrE1702 Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC... Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients prospective non interventional study comparing https://mlabs.umich.edu/tests/obsolete-alk-rearrangement-nsclc-fish OBSOLETE ALK Rearrangement for NSCLC by FISH | MLabs obsolete alk nsclc fish mlabs